Loading…
← CockpitCompetitor Analysis › 300436.SZ Fujian Cosunter Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Fujian Cosunter Pharmaceutical Co., Ltd. Class A300436.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Fujian-based pharmaceutical/biotech company; specific pipeline and products not fully confirmed from available knowledge.

Momentum laggard 11
Mkt cap
$2.02B
US dollars, full cap
Free float
72%
of shares outstanding
$/day
$32.7M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-28.2 pp
WACC 14.1%
Hurdle
n/a
no reverse DCF
Close · CNYCN¥67.56
1D0.0%
1W-12.5%
1M-14.7%
3M-32.9%
6M-44.8%
YTD-24.2%
1Y-39.6%
ATR %5.6%
52w lowhigh54.7% off high

What Fujian Cosunter Pharmaceutical does

Fujian-based pharmaceutical/biotech company; specific pipeline and products not fully confirmed from available knowledge.

Where it sits in the supply chain

  • Health Care
  • Biotechnology

What could go wrong

  • Loss-making biotech pipeline risk

Moat: none

Headquarters: Fujian, China · Employees: 715

Named competitors

Fujian Cosunter Pharmaceutical at a glance

Size Fujian Cosunter Pharmaceutical (300436.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $2.02B, the 1155th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥67.56 on 18 Nov 2026.

Performance Over six months the shares fell 44.8%, against -1.3% for the median peer and -20.0% for the China market (cap-weighted) — lowest of 21 in its peer set.

Growth Revenue fell 0.4% over the last twelve months (peer median +11.1%); the operating margin is -47.0% (peer median 22.2%).

Valuation It trades at 30.9× enterprise value to sales against a peer median of 4.8× (most expensive of 20).

Capital Return on invested capital runs 28.2 points below its cost of capital (14.1% WACC).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 97300436.SZ 55
Six months, rebased to 100: Fujian Cosunter Pharmaceutical against the median of its 20 peers (local-currency closes).

Fujian Cosunter Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥429MCN¥413MCN¥438MCN¥414MCN¥382M
Revenue growth—-6%+6%+8%—
Gross profitCN¥298MCN¥214MCN¥229MCN¥199MCN¥197M
EBITDAn/a-CN¥35.8M-CN¥46.2M-CN¥135M-CN¥173M
Net income-CN¥210M-CN¥218M-CN¥156M-CN¥349M-CN¥127M
Free cash flow-CN¥138M-CN¥94.6M-CN¥28.6M-CN¥376M-CN¥315M
Capital expenditureCN¥81.4MCN¥59.5MCN¥67.0MCN¥201MCN¥196M
Total debtCN¥485MCN¥728MCN¥697MCN¥696MCN¥313M

Quarterly statements and history in the cockpit →

Fujian Cosunter Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-10%0%+10%+20%6034566037070094209969600285ERISH02BHVNONESOURCEHRMY21445060020145400512SHILPAMEDALIVUSPFIZER300009600211COHANCE300436.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Fujian Cosunter Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%0×10×20×30×6034566037070094209969ERISH02ONESOURCEHRMY214450SHILPAMEDALIVUS300009COHANCE300436.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Fujian Cosunter Pharmaceutical is the large dot.

Fujian Cosunter Pharmaceutical competitors and peer comparison

Head to head with its named competitors (300436.SZ vs GILD vs 1177.HK)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Fujian Cosunter Pharmaceutical 300436.SZ$2.02B-45%0%-47%30.9×n/a
Gilead Sciences GILD$210B+30%+7%38%7.3×-2.4%
Sbp 1177.HK$12.2B+5%+15%30%2.6×-5.7%

How Fujian Cosunter Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Fujian Cosunter Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure300436.SZPeer medianRank in peer set
1-month return-14.7%+2.7%lowest of 21
6-month return-44.8%-1.3%lowest of 21
Distance from 52-week high-54.7%-28.2%lowest of 21
Revenue growth (TTM)-0.4%+11.1%4th lowest of 20
Operating margin-47.0%22.2%lowest of 20
EV / Sales30.9×4.8×most expensive of 20
ROIC minus cost of capital-28.2 pp+1.6 pplowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Fujian Cosunter Pharmaceutical 300436.SZChina$2.02B-45%0%-47%30.9×n/an/a
Zhejiang Jiuzhou Pharmaceutical 603456.SSChina$2.03B+19%-1%14%2.4×1.7%+15.7%
Nanjing King-friend Biochemical Pharmaceutical 603707.SSChina$2.03B-3%+9%14%3.2×5.1%+6.4%
Hanall Biopharma 009420.KSSouth Korea$2.01B+12%+5%3%16.6×n/an/a
InnoCare Pharma 9969.HKHong Kong$2.01B-10%+146%35%2.8×-2.0%+341.1%
Henan Lingrui Pharmaceutial 600285.SSChina$2.04B+9%+5%22%3.3×-4.7%+10.6%
Eris Lifesciences ERIS.NSIndia$1.98B0%+11%26%6.2×26.3%+20.9%
Haw Par H02.SISingapore$2.08B-25%-13%30%8.4×3.2%+15.7%
Biohaven BHVNUnited States$1.95B+46%n/an/an/an/an/a
OneSource Specialty Pharma ONESOURCE.NSIndia$1.95B-14%+11%6%11.8×n/an/a
Harmony Biosciences HRMYUnited States$1.94B+6%+20%22%1.4×-10.5%+40.3%
PharmaResearch 214450.KSSouth Korea$2.10B-24%+29%37%4.0×-11.0%+37.6%
Jinyu Bio-Technology 600201.SSChina$1.93B-21%+22%10%7.3×23.4%-2.5%
Tsumura & 4540.TJapan$1.93B+6%+13%18%2.0×n/an/a
Grand Pharmaceutical 0512.HKHong Kong$1.93B-25%+7%13%1.5×1.2%+14.1%
Shilpa Medicare SHILPAMED.NSIndia$1.91B+94%+37%21%10.1×n/an/a
Alivus Life Sciences ALIVUS.NSIndia$1.90B+36%+8%31%6.3×20.1%+6.2%
Pfizer PFIZER.NSIndia$1.88B-20%+12%34%5.5×11.2%+2.4%
Anhui Anke Biotechnology (Group) 300009.SZChina$1.88B-12%-9%30%4.8×8.0%+9.3%
Tibet Rhodiola Pharmaceutical 600211.SSChina$1.87B-8%+13%27%3.4×-1.2%+16.7%
Cohance Lifesciences COHANCE.NSIndia$1.87B+7%+14%2%8.6×n/an/a

Questions

Who are Fujian Cosunter Pharmaceutical's main competitors?
Named competitors: Gilead Sciences (GILD), Sino Biopharmaceutical (1177.HK). The cockpit's measured peer set (industry) also includes Zhejiang Jiuzhou Pharmaceutical (603456.SS), Nanjing King-friend Biochemical Pharmaceutical (603707.SS), Hanall Biopharma (009420.KS), InnoCare Pharma (9969.HK), Henan Lingrui Pharmaceutial (600285.SS), Eris Lifesciences (ERIS.NS).
Is Fujian Cosunter Pharmaceutical expensive compared with its peers?
On ev / sales it trades at 30.9× against a peer median of 4.8×, most expensive of 20 in its peer set.
How has Fujian Cosunter Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -44.8% against -1.3% for the median peer; over one year -39.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.